Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Adults with obesity receiving tirzepatide lost more than 25% of their body weight and were able to maintain their weight loss for up to 88 weeks, according to data from the SURMOUNT-4 trial. In ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

Tirzepatide’s dual trial win comes several months after the med passed the phase 3 SURMOUNT-2 study with flying colors, helping diabetic patients who are obese or overweight lose up to 15.7% of ...

Endocrinology > Obesity Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says — Dual GLP-1/GIP drug yielded an average 47% greater relative weight loss compared to ...

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on ...